热门资讯> 正文
Schrödinger扩大了Bristol Myers Squibb与人工智能联合科学家的合作伙伴关系
2026-08-05 21:14
- Schrödinger (SDGR) announced on Wednesday a strategic agreement with Bristol Myers Squibb to deploy its Bunsen agentic AI co-scientist across the company's research organization.
- The deal expands the companies' long-standing partnership and broadens the use of Schrödinger's computational platform in drug discovery.
- Schrödinger will work with Bristol Myers Squibb to add new features to Bunsen and connect it with its RetroSynth AI platform for molecule design and synthesis planning.
- Chief Scientific Officer Robert Abel said the agreement will help more scientists adopt AI and computational tools to accelerate drug discovery.
More on Schrödinger
- Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It
- Schrödinger: Surviving, If Not Thriving, In The Tricky AI Drug Discovery Field
- Schrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Schrödinger Q2 2026 Earnings Preview
- Seeking Alpha’s Quant Rating on Schrödinger
推荐文章
港股周报 | 黄金股狂飙！灵宝黄金周升24%；段永平“被动减持”泡泡玛特；药明康德升近20%创新高
一周财经日历 | 重磅财报周！腾讯、Lumentum、中芯国际轮番登场！美国7月CPI携零售数据来袭
8月8日外盘头条：伊朗内部辩论霍尔木兹协议措辞 非农爆冷削弱加息预期 SpaceX将自建发电厂保障电力供应
Palantir股价将创下自2024年以来最佳单周表现，该股已不再是AI领域的失意者
7月非农就业数据走弱，支持美联储维持利率不变，但加息选项并未彻底排除
美股前瞻 | 聚焦20：30！市场静候7月非农数据；特朗普政府拟加码布局关键矿产；应用光电计划大规模扩产，光通信盘前集体飙升
港股异动 | 创新药概念再度走强，再鼎新药劲升14%，Q2产品收入环比增长11%；药明生物升逾5%，百济神州升逾3%
港股异动 | AI硬件股多数上涨，建滔积层板、胜宏科技涨逾5%，兆易创新涨逾3%；南方两倍做多海力士跌逾9%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
